SynthesisBMC cardiovascular disorders2026
Antiplatelet therapy in acute coronary syndrome: a systematic critical appraisal of current guidelines.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThe purpose of this study was to critically assess acute coronary syndrome (ACS) antiplatelet therapy clinical practice guidelines (CPGs) and to compile the principal recommendations therein. MATERIALS AND
methodsWe systematically searched the literature between January 1, 2015 and June 29, 2025 to retrieve CPGs pertaining to antiplatelet therapy for ACS. Each CPG that met the inclusion criteria was subjected to a methodological quality assessment based on the six domains specified by the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool. The basic characteristics and proposed recommendations of each included CPG were systematically retrieved and subjected to comparative analysis.
resultsFrom the 8,190 records initially identified, a final set of 22 CPGs was deemed eligible for inclusion. The included CPGs achieved a mean AGREE II score of 70.3%. "Clarity of presentation" emerged as the highest-scoring domain (96.0%), whereas "editorial independence" was the lowest (53.5%). Antiplatelet treatment of ACS is related to the types of ACS, age, gender, treatment duration and bleeding risk. CPGs recommend dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist (ticagrelor, prasugrel, and clopidogrel).
conclusionsThere is considerable room for enhancing the methodological quality of CPGs focused on antiplatelet therapy for ACS. A dual antiplatelet therapy (DAPT) regimen comprising aspirin and a P2Y12 inhibitor was advised for the majority of patients presenting with ACS. Ticagrelor is the first-line choice, followed by prasugrel or clopidogrel as alternatives. In general, the duration of DAPT should be at least 12 months. Genetic testing and platelet function testing is not routinely recommended for ACS patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.